Acro Biomedical (ACBM) Equity Average (2017 - 2025)
Acro Biomedical has reported Equity Average over the past 9 years, most recently at -$409791.5 for Q4 2025.
- Quarterly results put Equity Average at -$409791.5 for Q4 2025, down 41.19% from a year ago — trailing twelve months through Dec 2025 was -$409791.5 (down 41.19% YoY), and the annual figure for FY2025 was -$340968.0, down 23.54%.
- Equity Average for Q4 2025 was -$409791.5 at Acro Biomedical, down from -$375069.5 in the prior quarter.
- Over the last five years, Equity Average for ACBM hit a ceiling of $657372.5 in Q1 2021 and a floor of -$409791.5 in Q4 2025.
- Median Equity Average over the past 5 years was $212649.8 (2023), compared with a mean of $145140.0.
- Biggest five-year swings in Equity Average: dropped 2.12% in 2022 and later crashed 661.67% in 2024.
- Acro Biomedical's Equity Average stood at $605962.5 in 2021, then fell by 19.26% to $489267.0 in 2022, then tumbled by 150.75% to -$248313.5 in 2023, then dropped by 16.88% to -$290238.0 in 2024, then plummeted by 41.19% to -$409791.5 in 2025.
- The last three reported values for Equity Average were -$409791.5 (Q4 2025), -$375069.5 (Q3 2025), and -$310713.0 (Q2 2025) per Business Quant data.